| Literature DB >> 30154315 |
Silvia Franzé1, Francesca Selmin2, Elena Samaritani3, Paola Minghetti4, Francesco Cilurzo5.
Abstract
Nowadays, the freeze-drying of liposome dispersions is still necessary to provide a solid dosage form intended for different routes of administration (i.e., parenteral, oral, nasal and/or pulmonary). However, after decades of studies the optimization of process conditions remains still challenging since the freezing and the dehydration destabilize the vesicle organization with the concomitant drug leakage. Starting from the thermal properties of phospholipids, this work reviews the main formulation and process parameters which can guarantee a product with suitable characteristics and increase the efficiency of the manufacturing process. In particular, an overview of the cryo- and/or lyo-protective mechanisms of several excipients and the possible use of co-solvent mixtures is provided. Attention is also focused on the imaging methods recently proposed to characterize the appearance of freeze-dried products and liposome dispersions upon reconstitution. The combination of such data would allow a better knowledge of the factors causing inter-vials variability in the attempt to improve the quality of the final medicinal product.Entities:
Keywords: QbD; cake appearance; cryoprotectant; freeze-drying; freezing rate; liposomes; lyoprotectant; solvent; stability; sublimation; time and temperature
Year: 2018 PMID: 30154315 PMCID: PMC6161153 DOI: 10.3390/pharmaceutics10030139
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Thermotropic behavior of phospholipid bilayer in an aqueous medium. T: pre-transition temperature, T: phase transition temperature.
Phase pre-transition (T) and transition (T) temperatures of fully hydrated phospholipids.
| Phospholipids | Acyl Chains | Ref. | ||
|---|---|---|---|---|
| DLPC | 12:0/12:0 | −1 | - | [ |
| DMPC | 14:0/14:0 | 24 | 22.0 | [ |
| DPPC | 16:0/16:0 | 40.5 | 35.5 | [ |
| DSPC | 18:0 | 49.1 | 54.5 | [ |
| DOPC | 18:1 | −18 | 9.0 | [ |
| HSPC | 16:0/18:0 | 53.6 | 47.8 | [ |
| EPC | Mixed chains | −15 to −20 | - | [ |
1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC); 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC); 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC); 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC); hydrogenated soy phosphocholine (HSEP); egg phosphocholine (EPC).
Figure 2Schematic representation of thermal events detectable by differential scanning calorimetry (DSC) in a simplified system: (A) typical trace of an amorphous protectant; (B) typical pattern of liposomes made of a phospholipid with a T significantly higher than melting ice temperature; (C) representation of an ideal thermogram registered on a liposome dispersion containing the protectant. T glass transition temperature of maximum freeze concentrate; T: pre-transition temperature of fully hydrated phospholipids; T: phase transition temperature of fully hydrated phospholipids.
Figure 3Cryo-transmission electron microphotographs of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)/cholesterol (60:40, mol/mol) liposomes prepared in water (a) and after addition of 10% (w/v) lactose to the external solution (b). The microphotograph shown in (c) was collected after freezing the liposome dispersion shown in (b). The black arrows denote peanut shapes structures, white arrows collapsed outer membrane of double liposomes and arrowhead in the inset of (b) denotes a completely collapsed liposome. Bars 1⁄4 100 nm. Reproduced with permission from [31], Elsevier Inc., 2010.
Figure 4Possible macro and micro appearance of cakes obtained by freeze drying. (A) Collapsed cake: total collapse (left) and partial collapse (center). The vial on the right shows no evidence of collapse; (B) SEM images of freeze-dried liposomes in presence of trehalose (S:L = 5:1) with a 200 times magnification (a); in presence of sucrose (S:L = 5:1) with a 250 times magnification (b); in presence of sucrose and mannitol (S:L = 5:1) with a 250 times magnification; no lyoprotectant (control) with a 200 times magnification (d); in presence of trehalose (S:L = 3:1) with a 200 times magnification, (e) respectively. S:L represents the carbohydrate to lipid molar ratio. The insert in red highlights the crystallized mannitol in sample (c). Reproduced with permission from [50,51], Elsevier Inc., 2018.
Figure 5Phospholipids bilayer before and after dehydration, with and without sugar.
Overview of the main excipients tested as protectants of liposomes upon freeze-drying. To allow a quick comparison of the data, it was arbitrarily assumed that the reconstitution is acceptable (Y) when a monodisperse population was obtained upon re-hydration and the hydrodynamic diameter of the resuspended liposomes was lower than 3 times with respect to the value of the not freeze-dried formulation. Leakage was considered avoided (effective) if the retention of the entrapped substance after freeze-drying was at least 90% of the original value.
| Protectant | Liposome Components | Effect | Ref. | |
|---|---|---|---|---|
| Reconstitution | Avoiding Leakage | |||
|
| POPC or DSPC: ls-PG: DSPE-PEG2000 | Y (5-10:1 | - | [ |
|
| POPC or DSPC: ls-PG: DSPE-PEG2000 | Y (5-10:1 | - | [ |
| [ | ||||
| [ | ||||
|
| POPC or DSPC: ls-PG: DSPE-PEG2000 | Y (5-10:1 | - | [ |
| DPPC:DPPG:CHOL | Y (5% | Effective (doxorubicin) | [ | |
| SPC or SPC:SPS or SPC:SPS:CHOL | Y (5% | - | [ | |
|
| DOPC or EPC | - | Ineffective (calcein) | [ |
| DPPC | - | Effective ( > 5:1 mol/mol) | [ | |
| DPPC:DPPG:CHOL | Y (5% | Effective (doxorubicin) | [ | |
|
| DPPC:DPPG:CHOL | Y (5% | Effective (doxorubicin) | [ |
| DOTAP:DOPE | Y (57:1 | - | [ | |
| EPC | Y (0-500 mg/mL) | ≥50 mg/mL (CF) | [ | |
| SPC:CHOL:DOTAP | Y (3-15:1 | Ineffective (ATP) | [ | |
| DPPC:CHOL:DSPE-PEG | Y (6:1 | Ineffective (prednisolone) | [ | |
| DOTAP:CHOL | Y (1.6-2.7:1 | Ineffective (decapeptide) | [ | |
| SPC | Y (5% | - | [ | |
|
| DPPC | Y (> 0.5:1) | Ineffective (CF) | [ |
| Y (5-10:1 | - | [ | ||
| Y (5% | Effective (doxorubicin) | [ | ||
| Y (57:1 | - | [ | ||
| Y (5-15:1 | Effective (< 10:1 | [ | ||
| Y (6:1 | Ineffective (prednisolone) | [ | ||
| Y (1.6-3.7:1 | Ineffective (decapeptide) | [ | ||
| Y (2-8:1 mol/mol) | Effective at 4:1 mol:mol | [ | ||
|
| DOPC or EPC | - | Ineffective (calcein) | [ |
|
| DOPC or EPC | - | Ineffective (calcein) | |
|
| DOPC or EPC | - | Ineffective (calcein) | |
|
| DOPC or EPC | - | Ineffective (calcein) | |
| DPPC | - | Ineffective (calcein, 75%) | [ | |
|
| EPC | Y (0-500 mg/mL) | Ineffective (CF) | [ |
|
| DOTAP:DOPE | Y (57:1 | - | [ |
|
| DOTAP:DOPE | Y (57:1 | - | |
|
| DOTAP:DOPE:DSPE-PEG | Y (57:1 | - | |
|
| DPPC or EPC | Y (5-15:1 | Ineffective (CF) | [ |
|
| DOTAP:DOPE | Y (57:1 | - | [ |
|
| DOTAP:DOPE | Y (57:1 | - | [ |
|
| DPPC:CHOL:DSPE-PEG | Y (6:1 | Effective (prednisolone) | [ |
|
| EPC | Y (30 mol %) | Ineffective (CF) | [ |
|
| EPC | Y (30 mol %) | Ineffective (CF) | [ |
|
| EPC or EPC:EPE or EPC:DLPE | Y (30 mol/mol) | Ineffective (CF) | [ |
|
| EPC or EPC:EPE or EPC:DLPE | Y (30 mol/mol) | Ineffective (CF) | [ |
|
| EPC:CHOL | Y (4:1 mol/mol, only) | Effective (ibuprofen) | [ |
|
| EPC:CHOL | Y (4:1 mol/mol) | Effective (ibuprofen) | [ |
|
| EPC:CHOL | Y (2-4:1 mol/mol) | Effective (4:1 mol:mol) | [ |
|
| SPC:CHOL | Y (5-20% | Effective (>10%, 94.2% CF) | [ |
Abbreviations: POPC: 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; DSPC: 1,2-distearoyl-sn-glycero-3-phosphocholine; ls-PG: 1-stearoyl-2-hydroxy-sn-glycero-3-[phospho-rac-1-glycerol]; DSPE-PEG2000: 1,2-distearoyl-sn-glycero-3-Phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000]; EPC: Egg yolk l-a-phosphatidylcholine; DOPC: Dioleoyl-t-c~-phosphatidylcholine; DPPC: dipalmitoyl-l-ce-phosphatidylcholine; DPPG: 1,2-dipalmitoyl-sn-glycero-3-phospho-(1′-rac-glycerol); CHOL: cholesterol; SPC: Soybean phosphatidylcholine; SPS: soybean phosphatidylserine; DOTAP: N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium; DOPE: 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; CF: carboxyfluorescein; DLPE: 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine; EPE: egg phosphatidylethanolamine; HSPC: l-α-phosphatidylcholine, hydrogenated (Soy); in/out: in, inside the liposome core; out, in the bulk medium. Y: Yes; N: No.
Collapse temperature (T), glass transition temperature of maximum freeze concentrate (T’) and water content remaining within an amorphous phase (W’) of various solutes (adapted from [75]).
| Compound | |||
|---|---|---|---|
| Glucose | −40 | −43 | 29.1 |
| Fructose | −48 | −42 | 49.0 |
| Sorbitol | −27 | −43 | 18.7 |
| Inositol | −27 | ||
| Sucrose | −32 | −32.0 | 35.9 |
| Lactose | −32 | −28.0 | 40.8 |
| Maltose | −32 | −29.5 | 20.0 |
| Raffinose | −26 | −26.5 | |
| Threalose | −29.5 | 16.7 | |
| Dextran | −9 | −9 | |
| HPβCD (hydroxypropyl-β-cyclodextrin) | −8 | −8 | |
| Poly(vinyl pyrrolidone) | −23 | −19.5 | |
| Poly(ethylene glycol) | −13 | −13 |
Figure 6Ishikawa diagram illustrating factors that have impact on the quality attributes of the final product. Reproduced with permission from [89], Informa UK Limited, 2017.
Figure 7Schematic representation of the factors influencing the critical quality attributes of freeze-dried liposomes.